Evidence map›Paper›PMID 36381334›Full record

ArticleAmerican journal of cancer research2022

MicroRNA-122 targets δ-catenin to suppress the tumorigenic potential of prostate cancer cells.

So-Yeon Park, Sung Jin Kim, Phuong Kim To, Rui Zhou, Kwonseop Kim, Kyung Keun Kim, Chaeyong Jung, Hangun Kim

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

So-Yeon ParkCollege of Pharmacy, Sunchon National University Sunchon 57922, Republic of Korea.
Sung Jin KimCollege of Pharmacy, Sunchon National University Sunchon 57922, Republic of Korea.
Phuong Kim ToDepartment of Anatomy, Chonnam National University Medical School Gwangju 61469, Republic of Korea.
Rui ZhouCollege of Pharmacy, Sunchon National University Sunchon 57922, Republic of Korea.
Kwonseop KimCollege of Pharmacy, Chonnam National University Gwangju 61186, Republic of Korea.
Kyung Keun KimDepartment of Pharmacology, Chonnam National University Medical School Gwangju 61469, Republic of Korea.
Chaeyong JungDepartment of Anatomy, Chonnam National University Medical School Gwangju 61469, Republic of Korea.
Hangun KimCollege of Pharmacy, Sunchon National University Sunchon 57922, Republic of Korea.
Chonnam National University · KRSunchon National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

δ-Catenin is expressed abundantly in various human cancers, including prostate, brain, breast, and lung carcinomas, and is recognized as an oncogene that promotes cancer cell growth and tumorigenesis. Although several transcriptional and post-translational pathways for δ-catenin regulation have been identified in cancer cells, the potential effects of microRNA-mediated regulation remain elusive. Here, we used a δ-catenin 3'-UTR luciferase reporter assay to identify regulatory microRNAs. Subsequent bioinformatics analyses and molecular studies revealed that overexpression of miR-122 downregulated δ-catenin expression significantly via targeted binding to a seed sequence in the 3'-UTR region of δ-catenin, and suppressed the invasion, migration, and proliferation of prostate cancer cells in vitro. In a TRAMP-C2 mouse syngeneic prostate tumor model, stable expression of miR-122 decreased both δ-catenin expression and tumor growth. Mechanistically, overexpression of miR-122 inhibited the expression of δ-catenin-mediated downstream factors significantly in prostate cancer cells, including c-myc and cyclin D1. In cells overexpressing miR-122, there was no additive or synergistic effect of siRNA-mediated knockdown of δ-catenin on cell invasiveness, and overexpression of miR-122 alone had a more pronounced suppressive effect on cell invasion than knockdown of δ-catenin alone. These results suggest that miR-122 acts as tumor suppressor in prostate cancer, mainly by downregulating δ-catenin expression, but also by targeting other factors. Indeed, subsequent experiments showed that overexpression of miR-122 reduced the levels of the mRNAs encoding myc, snail, and VEGF in prostate cancer cells. Overall, our findings demonstrate that targeting of δ-catenin by miR-122 represses the motility and tumorigenesis of prostate cancer cells, indicating a tumor suppressive effect of this miRNA in prostate cancer.

Indexed as

MicroRNAmiR-122motilityprostate cancertumorigenesisδ-catenin

Identifiers

PMID36381334
PMCPMC9641389
OpenAlexW4309243776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.